Is Satclizumab (Anshiping) manufactured in Japan?

Satralizumab (Satralizumab) is a drug developed by Chugai The recombinant humanized monoclonal antibody against the human interleukin-6 (IL-6) receptor developed by Pharmaceutical and Roche is uniquely formulated using "recycled antibody technology", in which the binding of satelizumab to the IL-6 receptor occurs in a pH-dependent manner, which allows satelizumab to bind to the IL-6 receptor until it reaches the endosome, after which the drug may be separated from the receptor and moved back into the plasma to play its role again.

Satlizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disease of the central nervous system (CNS) involving demyelinating lesions of the optic nerve, spinal cord, brainstem, and brain. Satclizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and the subsequent inflammatory response, similar to tocilizumab. This novel mechanism effectively extends the duration of action of satelizumab because it allows a single drug molecule to interact with multiple endogenous IL-6 receptors before being eliminated.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.